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Background: Globally, hypertensive disorders of pregnancy, particularly pre-eclampsia and eclampsia, are the leading
cause of maternal and neonatal mortality, and impose substantial burdens on the families of pregnant women, their
communities, and healthcare systems. The Community Level Interventions for Pre-eclampsia (CLIP) Trial evaluates a
package of care applied at both community and primary health centres to reduce maternal and perinatal disabilities
and deaths resulting from the failure to identify and manage pre-eclampsia at the community level. Economic
evaluation of health interventions can play a pivotal role in priority setting and inform policy decisions for
scale-up. At present, there is a paucity of published literature on the methodology of economic evaluation of
large, multi-country, community-based interventions in the area of maternal and perinatal health. This study
protocol describes the application of methodology for economic evaluation of the CLIP in South Asia and Africa.
Methods: A mixed-design approach i.e. cost-effectiveness analysis (CEA) and qualitative thematic analysis will be used
alongside the trial to prospectively evaluate the economic impact of CLIP from a societal perspective. Data on health
resource utilization, costs, and pregnancy outcomes will be collected through structured questionnaires embedded
into the pregnancy surveillance, cross-sectional survey and budgetary reviews. Qualitative data will be collected
through focus groups (FGs) with pregnant women, household male-decision makers, care providers, and district level
health decision makers. The incremental cost-effectiveness ratio will be calculated for healthcare system and societal
perspectives, taking into account the country-specific model inputs (costs and outcome) from the CLIP Trial. Emerging
themes from FGs will inform the design of the model, and help to interpret findings of the CEA.
Discussion: The World Health Organization (WHO) strongly recommends cost-effective interventions as a key aspect of
achieving Millennium Development Goal (MDG)-5 (i.e. 75 % reduction in maternal mortality from 1990 levels by 2015).
To date, most cost-effectiveness studies in this field have focused specifically on the diagnostic and clinical
management of pre-eclampsia, yet rarely on community-based interventions in low-and-middle-income countries
(LMICs). This study protocol will be of interest to public health scientists and health economists undertaking
community-based trials in the area of maternal and perinatal health, particularly in LMICs.
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Globally, hypertensive disorders of pregnancy (HDP),
particularly pre-eclampsia and eclampsia, are the leading
cause of maternal and neonatal mortality and impose sub-
stantial burdens on the families of pregnant women, their
communities, and healthcare systems [1, 2]. Pre-eclampsia
occurs when the pregnant woman has concurrent hyper-
tension and significant proteinuria [3]. In the absence of
early identification and timely case management of pre-
eclampsia, the trajectory can put women at high risk of
life-threatening complications [4]. Each year, it is esti-
mated that HDP complicates 10 million pregnancies,
resulting in 76,000 maternal and 500,000 foetal/newborn
deaths [5]. Nearly all of these deaths (>99 %) occur in low-
and-middle-income countries (LMICs), particularly in
South Asia and Sub-Saharan Africa [6].
Previously, the definitive management of HDP has fo-
cused on health facility level interventions with antihy-
pertensive [7] and anticonvulsant [8] therapies and timed
delivery to reduce risks. However, thousands of women
in hard-to-reach areas in resource-constrained LMICs
continue to suffer severe disability or lose their lives be-
cause of delays in early identification, triage, transport and
treatment—clinical processes that could feasibly be man-
aged within a woman’s own community at the level of a
primary health centre (PHC) or nearby via admission to a
more central referral hospital [9].
The CLIP Trial
The Community Level Interventions for Pre-eclampsia
(CLIP) is an ongoing cluster randomized trial [Clinical-
Trials.gov number ID NCT01911494] [10] that introduces
evidence-based interventions applied at both community
and PHC levels to reduce maternal and perinatal disabil-
ities and deaths resulting from the failure to identify and
manage pre-eclampsia at the community level. Specific-
ally, the CLIP intervention consists of:
I. Community engagement including women from the
communities, dyadic household decision-makers
(husbands, fathers-in-law) and community leaders
about: pre-eclampsia, its origins, symptoms, signs
and potential consequences, pre-permissions for
maternal transport and fundraising activities for
transport and treatment costs;
II. Provision of HDP-oriented antenatal care through
household visits by community healthcare providers
(cHCPs) who carry a mobile health application
for identifying women at risk of pre-eclampsia
[Pre-eclampsia Integrated Estimate of Risk
(PIERS) [11] on the Move (POM) [12] app];
III. Use of the CLIP package for women with a CLIP
‘trigger’ (i.e. oral antihypertensive therapy or
intramuscular (i.m.) magnesium sulphate (MgSO4)when indicated, and appropriate referral to a
comprehensive emergency obstetric care (CEMOC)
facility as needed).
The cHCPs assess pregnant women with a target fre-
quency of every 4 weeks at a minimum. These visits can
occur in the home or PHC, which are both considered
part of the community for the purpose of the CLIP Trial.
The cHCPs are trained to enquire about the woman’s
symptoms (using country-specific pictograms), take blood
pressure and check urine for protein using a dipstick on
the first visit or on any subsequent visits if the systolic
blood pressure is ≥140 mmHg. This helps to inform diag-
nosis of and risk assessment for pre-eclampsia. The con-
trol group (without intervention) continues with routine
pregnancy care related to antenatal visits, referral to a
health facility and initiation of therapy.
Cost and cost-effectiveness of interventions for
pre-eclampsia/eclampsia
Pre-eclampsia imposes very high financial burdens on the
families of the affected women and on the healthcare sys-
tem in LMICs [2, 13]. Economic studies conducted in the
United Kingdom (UK) report that pre-eclampsia/eclampsia
is one of the most common reasons for antenatal admis-
sion to hospital (20 %) and of obstetric admissions to
intensive care units (25 %) [14]. Other studies from the US
report that hospitalization costs for the management of pre-
eclampsia and associated complications were US$11,208
per woman on average [15, 16]. Studies from LMICs re-
port death or surviving serious illness of a mother to result
in lower household income [17] and to raise the risk of
death for children aged <10 years [18].
There are few cost-effectiveness studies related to pre-
eclampsia/eclampsia. Existing studies have focused on
diagnostic and clinical interventions in well-resourced
settings and not on other issues at community or popula-
tion levels. For example, a recent study from Israel evalu-
ated the economic benefit of first-trimester screening of
multiple markers compared with no screening. This study
found a cost per quality-adjusted life year (QALY) less
than US$10,000 for screening, given the prevalence of pre-
eclampsia at 3 % [19].
Another economic study in the context of the UK’s
National Health Service reported that the protein-creatinine
ratio (Pr:Cr) alone, when compared with automated reagent-
strip reading device followed by Pr:Cr and/or 24-h measure-
ment of proteinuria, was found less costly and gained the
most QALYs [20].
A large multi-country trial on prophylactic use of MgSO4
in women with pre-eclampsia reported the incremental
cost of preventing one case of eclampsia as US$21,202
in high-income, US$2473 in middle-income and US$456
in low-income countries [21]. Another study from the
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to all women with pre-eclampsia had an incremen-
tal cost of US$9994 for each additional seizure pre-
vented [22].
Other interventions in the context of the UK, such as
treatment with aspirin compared with no aspirin, were
found to be cost saving (i.e. £7852) and resulted in 0.52
additional QALYs per pregnancy in women at risk of pre-
eclampsia [23]. The labour induction for immediate birth
versus clinical management strategy was found to have an
incremental cost-effective ratio (ICER) of £2900 per QALY
gained in women diagnosed with mild or moderate pre-
eclampsia [24].
Cost-effectiveness studies have also evaluated other in-
terventions that can be used to improve maternal [25] and
neonatal health [26] in LMICs. However, their relevance
to pre-eclampsia/eclampsia interventions is limited given
the restricted analysis of individual interventions on surro-
gate health outcomes and the variability of settings.
In relation to the proposed work, our literature review
found very limited information for cost-effective inter-
ventions for pre-eclampsia/eclampsia in the context of
LMICs, which is where most of the disease burden and
associated mortality occur. Thus, it is critical to conduct
an economic evaluation alongside of the CLIP Trial, to
inform decision makers not only of clinical outcomes
but the cost required to obtain those outcomes.
Rationale for conducting economic evaluation of CLIP
Adam et al. [27] conducted a cost-effectiveness analysis
of WHO-recommended strategies for maternal and neo-
natal health and demonstrated the benefits of comprehen-
sive community-based antenatal, intrapartum and postnatal
interventions for reducing maternal and neonatal mor-
tality in sub-Saharan Africa and Southeast Asia. They
highlighted that packages of maternal and newborn in-
terventions can be more cost-effective than singular
interventions.
In our context, the CLIP Trial combines a package of
otherwise singular evidence-based interventions (blood
pressure monitoring [15], urine dipstick testing [28], MgSO4
[21], methyldopa [29], mobile health (mHealth) technol-
ogy [12, 30], antenatal visits by cHCPs [18], community
engagement [31], timely referral and triage at a health
facility [6]). This combined package of care must be evalu-
ated to determine if it is a cost-effective intervention in re-
ducing maternal and perinatal mortality.
It is well recognized that economic studies embedded
within clinical trials have high internal validity and time-
liness [32]. In this context, the International Society for
Pharmacoeconomics and Outcome Research (ISPOR) rec-
ommended collecting trial outcome data, health resources
used and health state utilities directly from the study par-
ticipants recruited in the trial [33].The CLIP Trial is being conducted across four countries,
and so assessment of the economic impact (costs and
benefits) alongside the trial (i.e. concurrent with it) will
be integral to building a robust cost-effectiveness model
to supplement the trial outcomes. This is critical be-
cause the CLIP Trial introduces new costs in health
service delivery (e.g. mHealth and task shifting to
cHCPs), which will have budgetary implications for
health systems in the selected CLIP countries. Post-
trial program scale-up of CLIP interventions must be
informed through both the impact of the package of
intervention and the cost of achieving any incremen-
tal benefits in the context of selected South Asian and
African countries.
The CLIP Trial’s collaborating partners and Ministries
of Health (MoH) in the respective countries have a clear
desire to ascertain the long-term implications of the
CLIP package of care. These stakeholders unanimously
endorsed conducting an economic appraisal of CLIP to
further inform policy decisions around resource alloca-
tion and program scale-up, thereby serving as models
for other LMICs.
Study hypothesis
The CLIP package combined with routine pregnancy
care, compared to routine pregnancy care alone, will re-
sult in a favourable (i.e. low) ICER in reducing maternal
and perinatal mortality and major morbidities.
Study objectives
The primary objectives are to:
1a) Determine the costs and benefits of the CLIP package
of care in order to design the cost-effectiveness
model;
1b) Estimate the ICER of the CLIP plus routine
pregnancy care, compared with routine pregnancy
care alone, in reducing maternal and perinatal
mortality and major morbidities;
1c) Assess health system budget impact, when
switching from routine pregnancy care to CLIP
plus routine pregnancy care.
The secondary objectives are to:
2a) Qualitatively identify the cost drivers (resources
needed) during trial implementation to inform
design of the model;
2b) Explore implementation challenges and perceived
cost-benefits of CLIP plus routine pregnancy;
2c) Inform health decision/policy makers about the
findings of cost-effectiveness of the CLIP package of
care and budgetary implications in the selected
countries.
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Research design
We propose to use CEA in conjunction with qualitative
analysis alongside the trial to prospectively evaluate the
economic impact of CLIP. Qualitative research has been
used effectively in other cluster RCTs to assess the im-
plementation variations and local context of the inter-
vention [34]. We will use a mixed-method approach
because the CLIP Trial is being conducted in four countries
that have different health delivery systems, health financing,
resource allocation interests, diversity of community beliefs
about pre-eclampsia/eclampsia, care-seeking behaviours
and treatment preferences. The mixed-method approach
(CEA and qualitative) will inform the design of modelling
and support interpretation of economic analysis for deci-
sion makers who are considering evidence of economic
value along with the effectiveness of CLIP.
Research plan
The research will be conducted in three inter-linked
phases over a 2-year period. (Please refer to Fig. 1).
Phase 1 will contribute to objective 1a using cost esti-
mation and outcome monitoring methods to design a
cost-effectiveness model for CLIP. Qualitative assessments
will address objectives 2a and 2b to understand contextual
aspects of the costs, challenges during trial implementa-
tion and benefits from community perspectives to support
interpretation of the economic analysis. Phase 1 activities
will be undertaken in Pakistan, one of the four countries
engaged in the CLIP Trial.
In Phase 2, based on the learning in Phase 1, we will
use similar, but contextually modified, methods guided
by within-country data collection to validate/extrapolateFig. 1 Research plan for economic evaluation of the CLIPthe cost-effectiveness model in the other three sites
(i.e. India, Nigeria and Mozambique).
Phase 3 will address Objectives 1b and 1c, once the final
trial outcomes are analysed and available to run the cost-
effectiveness analysis for all sites. In addition, it will address
Objective 2c to inform health decision/policy makers about
cost-effectiveness and budgetary implications.
Target population
Because pre-eclampsia is a pregnancy-related illness, this
study will target pregnant women aged 15–49 years (ex-
cept Mozambique where the eligibility age is 12–49 years),
those recruited in the primary CLIP Trial in both inter-
vention and control clusters.
Settings and duration
The sites for the CLIP Trial include local government
areas of Ogun State, Nigeria; the Provinces of Gaza and
Maputo in Mozambique; the districts of Matiari and
Hyderabad in the Province of Sindh, Pakistan; and the
Belgaum and Bagalkot districts in the State of Karnataka,
India. The economic evaluation of CLIP will be a critical
step to guide policy decisions for post-trial program
scale-up in all of these selected countries.
The total duration of the proposed country-specific
cost-effectiveness analysis will be 2 years (Sept 2015–Aug
2017) (please refer to Table 1). Phase 1 will commence in
September 2015 and will include activities for cost calcula-
tion and qualitative assessments at one site. The data from
phase 1 will be analysed by April 2016. Phase 2 will com-
mence in May 2016 at the remaining three CLIP sites
and shall be completed by December 2016. Finally, the
country-specific CEA will be completed by June 2017,
Table 1 Project milestones (GANTT chart) for economic evaluation of the CLIP
2015 2016 2017
1–4 (Sep–Dec) 5–8 (Jan–Apr) 9–16 (May–Dec) 17–22 (Jan–June) 23–24 (Jul–Aug)
Phase I Phase II Phase III
Designing/Testing the
costing model (Pakistan only)
Validation/Extrapolation of the costing
model (India, Nigeria, and Mozambique)
Determining an evidence for economic impact
of the CLIP (All four sites)
Field level planning; and
conducting qualitative
focus groups (FGs) and
data analysis
Collecting costing
data and data analysis
Conducting FGs; and
collecting cost data
Data analysis
and extrapolation
of model
Generating country-specific
cost-effectiveness models
Writing report; and
conducting final result
dissemination seminar
-Calculating incremental cost
per combined maternal/
perinatal outcomes averted
-Baseline survey for
cost estimation
-FGs with community
-FGs with health
providers -FGD with
Policy makers community
and health workers
-Model validation-Collecting price list
for health services
-Review of district
level cHCP budget
-Calculating incremental
cost per DALY gained.
Country-specific budgetary
analysis
-FGs with community-Baseline survey for
cost estimation
-Collecting price list
for health services
-Review of district
level cHCP budget
-Designing/Testing
the model
-FGs with health
providers
-FGD with
Policy makers
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August 2017.
Study perspective
The CEA will be based on a societal perspective, account-
ing for both costs to healthcare system and cost to families
of the pregnant women.
Designing the model: description of cost variables
The standardized ingredient approach [35], which involves
gathering sufficient information about the quantities and
unit cost of physical inputs needed in the intervention
and control groups, will be used to calculate costs. This
will include cost to the healthcare system and cost to
the family.
Cost to the healthcare system
The cost to the health system will comprise the cost of the
CLIP Trial interventions, including mHealth technology
and infrastructure, blood pressure devices, urine dipsticks,
community engagement sessions, training and time of
healthcare providers at the community and health facility
levels. Additional costs will include:
– Cost of follow-up household visits and time spent
on blood pressure monitoring/urine dipstick by
cHCPs in each of the selected sites, such as
Community Health Extension Workers (CHEW) inNigeria, Agente Polivalente Elementar (community
health agents) in Mozambique, Lady Health Workers
(LHW) in Pakistan and Accredited Social Health
Activists (ASHA) in India;
– Cost of cHCPs’ additional time and transport costs
when accompanying any identified HDP woman to a
referral health facility;
– Health system costs such as managing triage for
obstetric emergencies, in-patient/outpatient services
for obstetric emergencies, as well as diagnostic tests
and drugs.Cost to the family
All relevant out-of-pocket (OOP) expenses for ambu-
lance, hospitalization (physician fees, bed charges, nurs-
ing services), drugs and diagnostic workup related to
care from the referral health facility would be included.
Also, OOP cost for informal care (i.e. care sought from
traditional healers) will be captured, as well as the cost
of lost productivity resulting from morbidity or mortality
of patients with or without paid jobs, and any lost wages
of their caregivers.Cost to society
The total societal costs (i.e. combining of costs to the
healthcare system and cost to the family) will be calcu-
lated by summing across all cost categories.
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This study will compare the costs and pregnancy out-
comes ascertained from the intervention i.e. CLIP plus
routine pregnancy care; compared with control group
i.e. routine pregnancy care alone. In a primary CLIP
cluster-randomized trial, the interventions are being
evaluated at the population level. Therefore, people in
the comparator group will continue to receive routine
pregnancy care related to antenatal visits, referral to a
health facility and initiation of therapy.
Health resource utilization and costs: data collection
methods
The information about resources utilized and unit costs will
be collected from primary and secondary data sources in
the intervention and control groups. A consistent ap-
proach will be followed to collect these data in the inter-
vention and control clusters, except for POM utilization,
which only occurs in the intervention clusters (see
Table 2).
Health resource utilization data
Structured health resource utilization questionnaires are
embedded into CLIP Trial surveillance forms and will be
administered to all pregnant women recruited in interven-
tion and control clusters. These questionnaires have been
translated into study site languages (Yoruba in Nigeria,
Portuguese in Mozambique, Sindhi/Urdu in Pakistan and
Kannada in India) and are as follows:
Form 1: Pregnancy registration: Project research staff
will complete this form only once for every pregnancy
identified during the trial period in the interventionTable 2 Methods for collecting resource utilization and cost
information
Type of data Intervention group Control
group
Health resource
utilization
Health resource utilization questionnaire integrated
with CLIP Trial quarterly surveillance tools for
intervention and control groups:
Form 1: Pregnancy Registration
Form 2: Regular community surveillance
Form 3: Health facility utilization
PIERS on the move (POM) data N/A
Unit costs Cross-sectional household survey for family’s
out-of-pocket expenses
Review of price listing for diagnostic and
clinical services offered at health facilities
Review of district level program budget
(costing for cHCP salaries)
Review of site-specific CLIP Trial budget
(costing for intervention package)
N/Aand control groups. The key variables include health
resource utilization, such as frequency of hospital visits,
type of health facility (public or private), level of health
facility (primary, secondary, or tertiary), level of care
(in-patient or out-patient), length of stay, diagnostic
tests and clinical interventions since conception to
the time of pregnancy registration. Also, information
will be collected on mode of transport, number of
accompanying family members and days of missed
wages.
Form 2: Regular community surveillance: Project staff
will complete this form once every 3 months until
delivery and once post-delivery capturing data for the
42 days after childbirth, for each pregnant woman re-
cruited in the intervention and control groups. The key
variables include health resource utilization, such as
frequency of hospital visits, type of health facility (pub-
lic or private), level of health facility (primary, second-
ary, or tertiary), level of care (in-patient or out-patient),
length of stay, diagnostic tests and clinical interventions
for pregnant women and newborn. Also, information
will be collected on mode of transport used, number of
accompanying family members and days of missed
wages.
Form 3: Health facility utilization: This is based on
patient hospital admission chart review for women
recruited in the CLIP Trial and will be completed by
project research staff during their monthly visits at all
referral health facilities in the catchments of
intervention and control groups. The key variables
include diagnostic and clinical services utilized by
pregnant women and/or newborns at health facilities.
The POM data
The information about resource utilization as a result of
CLIP interventions will be captured from the POM data
set. Based on clinical triggers, CLIP interventions are clas-
sified into five main categories: 1) treat with MgSO4 and
transport to hospital; 2) urgent transport (within 4 h) to
hospital only; 3) non-urgent transport (within 24 h) to
hospital only; 4) treat with MgSO4 and methyldopa and
transport to hospital; and 5) continue with routine ante-
natal care. POM data is maintained electronically for all
the women recruited in the intervention clusters.
Cross-sectional household survey
The survey will be conducted in a sample of women from
intervention and control clusters to determine unit costs
for out-of-pocket expenses to the family associated with
obstetric emergencies including HDP. The value of the
lost wages will be estimated by using a mean wage rate to
missed work time, obtained from country-specific stan-
dards. Assuming an incidence rate of pre-eclampsia at 8 %,
95 % confidence interval and design effect of 1.0 for a
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line survey at each site is presented in Table 3.
Review of price listing for maternal and newborn health
services
In order to obtain the unit cost of hospitalizations (e.g.
bed charges, nursing services), drugs and diagnostics,
the price lists will be obtained from all public and pri-
vate health facilities where women with HDP will be re-
ferred in the catchments of intervention and control
clusters. The weighted average will be calculated for esti-
mating unit costs for similar types of services available
at private and public health facilities, with respect to the
number of women utilizing such services for pregnancy
care, delivery and newborn care.
Reviewing district level cHCP program budget
The salaries of cHCPs who are currently involved in the
CLIP Trial will be determined through review of the dis-
trict level program budget. Where resources are shared
with other preventive programs, we will use simultan-
eous allocation methods for determining the unit cost of
applicable services. In addition, the transport expenses
will be calculated for the extra visits of cHCPs in the
intervention clusters to be able to determine the cost of
task shifting.
Review of site-specific CLIP Trial budget
The unit cost estimates for the CLIP Trial intervention
package include the cost of a blood pressure device,
urine dipstick, oxygen saturation prop, cost of commu-
nity engagement sessions, and cost of training doctors,
nurses, midwives and community health workers and
will be determined from the trial budget for each site in
the CLIP Trial. These cost estimates will be verified
from the central trial office (PRE-EMPT, UBC).
Designing the model: qualitative data collection methods
Focus groups (FGs) are a commonly used method of
data collection in qualitative research to gather group
opinions [36]. Specifically, the FGs in this study are
aimed to better understand the contextual variations of
intervention delivery, resources used for costing work
and perceived benefits from a community perspective.Table 3 Site-specific population and desired number of women for
Variables P
Total population per cluster
Number of intervention and control clusters
Annual birth rate (/1000/year)
Total number births during trial period
Estimated number of women with pre-eclampsia during trial period
Number of women required for surveyBesides healthcare providers and care receivers in a
community, studies have reported that women in LMICs
are situated in cultural contexts, where men in their lives
are traditionally the decision makers surrounding
women’s health issues [37]. As inclusively as possible,
the community perspectives will be obtained from
groups of:
– Pregnant women identified as at risk due to a HDP;
– Male decision makers (husbands/fathers-in-law) of
pregnant women identified as at risk of a HDP;
– Community healthcare providers;
– Medical doctors at referral health facilities;
– District-level health decision/policy makers.
Guided by relevant literature [37, 38], and investiga-
tors’ experiences of CLIP Trial feasibility work in the
CLIP countries, semi-structured interview guides have
been developed following a priori themes:
Theme I: Cost drivers and health resource utilization as
a result of the CLIP package.
Theme II: Perceived benefits of the CLIP package of
care and task shifting to cHCPs.
Theme III: Implementation challenges for the CLIP
package of care.
Theme IV: Strategies for knowledge translation of CLIP
to the wider community.
Theme V: Strategies for health policy advocacy and
program scale-up of CLIP.
The FG guides will be translated into local languages
and pilot tested in randomly selected intervention clus-
ters before data collection. Digital voice recorders and
written notes will be used to record the participants’ re-
sponses during all FGs. The FG data will be transcribed
into the local language, followed by translation into English.
All the translations will be confirmed by researchers with
back-translation of randomly selected data segments for
quality control.
Study eligibility (inclusion and exclusion criteria)
Pregnant women aged 15–49 years (except Mozambique
where the eligibility age is 12–49 years) recruited in thesurvey
akistan India Nigeria Mozambique Total
32,000 27,000 70,000 25,000 154,000
20 12 10 12 54
14 22 16 40 92
19,800 19,200 26,880 24,400 90,280
1584 1536 2150 1952 7220
113 113 136 126 488
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be eligible to take part in the economic data collection
(i.e. Form 1, Form 2 and Form 3) for health resource
utilization. For qualitative assessments, eligible participants
include only women in the CLIP intervention group who
were identified as at risk of a HDP. Likewise, male decision
makers of pregnant women (identified as at risk of a HDP)
and those willing to participate in the session will be eli-
gible. The cHCP handling the CLIP Trial package of inter-
vention, the medical doctors at the referral health facilities
and district health decision makers in the catchments of
intervention and control groups and those willing to par-
ticipate in 45- to 60-min session will be eligible to partici-
pate. Participants who will be excluded are those who
are not recruited in the primary CLIP Trial and/or re-
fused to take part in the economic data collection proce-
dures. The eligible participants for qualitative assessments
will be approached by project research staff during home
and health facility visits for CLIP Trial surveillance and
will be invited to participate in FGs.
Sample size
The sample size required to demonstrate the effective-
ness of the primary CLIP Trial will be sufficient as it is
powered to detect 30 % effect size. We estimate a total
of 90,000 pregnant women will be registered in the CLIP
Trial across four sites; and those who consent to surveil-
lance (Form 1, 2, and 3) will be included in our eco-
nomic analysis.
Each FG will include 6–9 participants. We anticipate a
total of 40 FGs inclusive of all groups; however, the final
number of FGs will be determined by data saturation
(see Table 4).
Outcome variables (effectiveness): methods of collecting
outcomes
The CLIP Trial primary outcome is the reduction in com-
bined maternal and/or perinatal adverse outcomes be-
tween the intervention and control groups (see Table 5).
The project research staff will assess the trial outcomes
every 3 months during community surveillance visits at
the households for all women recruited in the intervention
and controls groups.Table 4 Number and distribution of FGs across CLIP countries
CLIP country Number of focus groups (anticipated)
Pregnant women
with HDP
Male decision
makers
Communi
providers
Pakistan 2 2
India 2 2
Nigeria 2 2
Mozambique 2 2
Total 8 8Data analysis
Because outcomes of pregnancy can be assessed over a
short span (i.e. 40–42 weeks of time horizon), the decision
analytic tree model [39] can be used for comparative ana-
lysis of costs and effectiveness between two alternatives.
Previously conducted cost-effectiveness studies for pre-
eclampsia [19, 22] have mainly used a decision analytic tree
model. Our primary analysis for this study will be model
based, guided by previous work in high-income countries
as no LMIC modelling in pre-eclampsia has been done.
We will use parameter estimates for costs and effectiveness
coming from the CLIP Trial (see Fig. 2).
The unit costs will be multiplied by identified health
resource utilization to calculate the total cost per preg-
nancy, including both pregnant woman and newborns.
The total cost will be calculated as the sum of the health
resource utilization cost, cost of implementing the CLIP
package of care, cost of routine pregnancy care and soci-
etal costs. The annual equivalent costs in local cur-
rency of selected CLIP countries (PKR—Pakistani Rupee;
INR—Indian Rupee, NGN—Nigerian Naira and MZN—
Mozambican Metical) will be converted in US dollar
exchange rate as of 2015. The pregnancy outcomes
(i.e. health of mother and baby) will be modelled as the ef-
fectiveness of the CLIP interventions. This will include
no-adverse outcomes (healthy mum and newborn at the
time of delivery) and adverse outcomes (death and/or dis-
ability of mother and baby) observed in the intervention
and control groups.
In addition, costs and pregnancy outcomes will be mod-
elled over the lifetime horizon to estimate the long-term
impact of CLIP. We will calculate disability-adjusted life
years (DALYs) averted through subsequent modelling to
yield estimates of the years of life lost due to disabil-
ity [40] taking into account the epidemiological rates and
health state valuations on burden of disease for African
and South Asian regions [41, 42]. Both costs and out-
comes will be discounted at 3 % per year, the widely cited
discount estimate for economic studies in the context of
LMICs [26, 43].
Using the data and parameter estimates specific to each
CLIP country, the ICERs will be calculated first from a
healthcare system perspective and then from a societalTotal
ty healthcare Doctors at health
facilities
District health
decision makers
2 2 2 10
2 2 2 10
2 2 2 10
2 2 2 10
8 8 8 40
Table 5 Definitions of CLIP Trial outcomes
Definitions
Maternal outcomes
Mortality Defined as the number of deaths during pregnancy or within 42 days of pregnancy (or last contact day if contact not maintained
to 42 days)/1000 identified pregnancies), termed maternal death rate.
Morbidities Defined as the number of women with one or more life-threatening complications of pregnancy during pregnancy or within
42 days of pregnancy/1000 identified pregnancies.
Serious end-organ complications of pre-eclampsia:
Eclampsia: occurrence of generalized convulsions during pregnancy, labour or within 42 days of delivery in the absence
of epilepsy or another condition predisposing to convulsions
Stroke: hemiparesis and/or blindness developed during pregnancy or in the 42 days postpartum lasting greater than 48 h
Coma: prolonged unconsciousness ≥12 h
Antepartum haemorrhage: vaginal bleeding ≥15 mL with or without pain before the onset of labour
Disseminated intravascular coagulation (DIC): abnormal bleeding from mucosa (mouth and/or ears)
Other major causes of maternal mortality:
Obstetric sepsis: In the community, defined as fever and one of: abdominal/uterine tenderness, foul smelling vaginal
discharge/lochia, productive cough and shortness of breath, dysuria or flank pain, headache and neck stiffness. In the facility,
defined as presence of fever (>38 °C), a confirmed or suspected infection (e.g. chorioamnionitis, septic abortion, endometritis,
pneumonia) and at least one of the following: heart rate >90/min, respiratory rate >20/min, leukopoenia (total leukocyte
count [TLC] <4 × 109/L) or leukocytosis (TLC >12 × 109/L)
Vesicovaginal or rectovaginal fistula: continuous loss of urine and/or faeces after delivery
Life-saving interventions:
Cardiopulmonary resuscitation: a set of emergency procedures including chest compressions and lung ventilation applied
in cardiac arrest victims
Dialysis: haemodialysis and/or peritoneal dialysis
Mechanical ventilation (other than for Caesarean section): intubation and ventilation not related to anaesthesia
Blood transfusion: ≥1 unit
Interventions for major postpartum haemorrhage: brace sutures, external and internal uterine compression, anti-shock
garment use, internal iliac artery ligation and/or hysterectomy with or without transfusion
Perinatal outcomes
Mortality Defined as stillbirth [≥20+0 and/or ≥500 g], early neonatal mortality [days 0–7 of postnatal life] and late neonatal mortality
[days 8–28 of postnatal life]/1000 identified pregnancies]
Morbidity Defined as non-lethal events of seizure and coma during days 0–28 of postnatal life/1000 identified pregnancies). The following
are the primary neonatal morbidities:
Feeding difficulty
Breathing difficulty
Seizure
Lethargy
Coma
Fever
Hypothermia
Umbilical cord infection
Skin infection
Bleeding
Jaundice
Vomiting/Diarrhoea
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Fig. 2 Decision analytic tree model for economic evaluation of CLIP. HDP, hypertensive disorder of pregnancy
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as follows:
(i) Incremental cost per adverse pregnancy outcome
(ii) Incremental cost per DALY gained
ICERs for the system perspective as the reference case
will be of interest to country-specific health policy makers
for resource allocation decisions, when switching from rou-
tine pregnancy care to CLIP plus routine pregnancy care,
should CLIP be found effective. Critically, however, the
ICER from a societal perspective will facilitate discourse
on the full opportunity cost in the context of the selected
CLIP country. In accord with the recommendation of the
Commission for Macroeconomics and Health [44], we will
compare the country-specific ICER with the per capita
value for the gross national income of each of the four se-
lected CLIP countries for the year 2015.
Given the uncertainties involved in CEA, we will use
probabilistic sensitivity analysis to produce cost-effectiveness
plots [45]. The confidence region surrounding the cost-
effectiveness ratio will be estimated using appropriate stat-
istical methods, including bootstrap and Monte Carlo
simulations. Life tables based on data from the World
Health Organization’s Southeast Asia and African regionsFig. 3 Map of interventional studies on the topic of maternal health—thos[46] or the West level-26 model [47] will also be used in a
sensitivity analysis. Children in LMICs bear a dispropor-
tionately large share of the total disease burden, because
of the cause structure of the disease burden by age could
influence overall distribution of DALYs [48]. As reported
on previous cost-effectiveness studies in LMIC, no-age-
weighting in the reference case was used on sensitivity
analysis [43]. Country-specific health system budget im-
pact analysis will be conducted to facilitate policy deci-
sions for resource allocation, when switching from routine
pregnancy care to CLIP plus routine care, should the
intervention be found effective.
Qualitative data will be analysed using QSR NVivo v10
software, and responses will be coded to form similar
categories. These will be refined through thematic ana-
lysis. Data will be interpreted through close communica-
tion between local researchers and international team to
ensure accuracy.
Ethical considerations
This study will utilize the existing CLIP Trial infrastruc-
ture in the four countries and follow the human ethics
protocol for the randomized control trial. There is no
physical harm and risk to participants in this economic
study. The Institutional Review Board (IRB) approval frome registered with ClinicalTrials.gov
Khowaja et al. Implementation Science  (2015) 10:76 Page 12 of 14UBC has been obtained [ETHICS # H12-00132] for the
economic evaluation of the CLIP. In addition, the country-
specific formal letters of support and permission for data
access have been received from government health author-
ities in all four CLIP countries. Study questionnaire and
data forms will be kept in a secured place accessible only
to study staff. No personal identifiers will be used in any
reports or publications. Study procedures and benefits will
be explained to the study participants, and written consent
will be obtained for the baseline cost estimation survey
and for qualitative FGs in this study.
Trial status
The CLIP Trial has been registered at ClinicalTrials.gov
(NCT01911494). It is funded by the Bill & Melinda Gates
Foundation. The definitive phase of the CLIP Trial is cur-
rently recruiting at all four sites and shall continue until
December 2016. The recruitment began in India on 1
November 2014, in Pakistan on 19 January 2015, in
Mozambique on 1 March 2015 and in Nigeria on 15
March 2015.
Discussion
Economic evaluation of innovative health interventions
can play a pivotal role in priority setting and can inform
healthcare decision makers with evidence relevant to re-
source allocation [49]. The World Health Organization
(WHO) strongly recommends cost-effective interventions
as a key aspect of achieving Millennium Development
Goal (MDG)-5 (i.e. 75 % reduction in maternal mortality
from 1990 levels by 2015) [50]. Our search for interven-
tion studies registered on ClinicalTrials.gov revealed 1588
studies that mentioned “maternal health” on the submitted
protocols [51]. Of these, 36 % were reported from Africa
and South Asia, which is where most of the maternal
mortality burden occurs [1] (see Fig. 3). Only 28 out
of 1588 (i.e. ~2 %) included “cost-effectiveness analysis”
on the submitted protocols.
Given this, it seems that few recent maternal health
intervention studies have looked at how cost-effectiveness
these interventions may be to scale up. This is contrary to
the recommendations of WHO for maternal health inter-
ventions and indicates a large knowledge gap for policy
decisions. Consequently, the CLIP Trial is one of the
first large-scale research trials to address this important
question in the real-world context in LMICs, and thus
provides a unique and timely opportunity for economic
evaluation of a well-designed community-based trial that
directly aligns with MDG-5.
Possible study limitations
There is a possibility of recall bias for the cost to family
obtained on the baseline survey; however, we will limit
the recall length to the most recent hospitalization. Inaddition, some non-financial factors, such as patient and
provider preferences and altruism, could possibly influ-
ence families’ healthcare utilization. The methodological
consistency in collecting costs and outcomes in both inter-
vention and control groups, supplemented by the qualita-
tive data for designing the cost-effectiveness model for
each site, will increase the internal study validity.
Knowledge translation
Results of the economic impact analyses will be communi-
cated to community stakeholders, providers and policy
makers through dissemination workshops organized in
each country site after CEA results have been completed.
Policy briefs [52] will also be drafted to highlight key find-
ings, and they will be distributed among healthcare pro-
viders and district health authorities in other provinces in
each country. The progress of the study, findings from in-
terim analysis and final CEA results, will be presented at
relevant national/international conferences. Manuscripts
will be submitted for publication in peer-reviewed open
access journals.
Potential impact
This study will definitively determine the costs incurred
by the CLIP package of care and the number of mater-
nal/perinatal deaths and major morbidities averted per
US dollar. In the long run, this study will supplement the
scientific evidence around the effectiveness of the inter-
vention and so facilitate policies which best mobilize local
technology and employ human resources for maximizing
healthy pregnancy outcomes in the selected LMIC coun-
tries. The qualitative findings will help to interpret the
cost benefit findings of the CLIP Trial, to identify chal-
lenges during trial implementation and to strategize
knowledge translation for strengthening policy advocacy
for post-trial programmatic scale-up and sustained imple-
mentation within existing maternal health policies in the
selected CLIP countries. Furthermore, we will have robust
data to propagate similar models for other non-CLIP
LMICs in the developing world.
Endnotes
1DALYs are defined as a measure of overall disease
burden, expressed as the number of years lost due to ill
health, disability or early death.
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